Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress™) on the course of progressive feline leukemia virus infection

Veterinary Microbiology

Volumn 175, Issue 2-4, 2015, Pages 167-178

  Boesch, Andrea ^a   Cattori, Valentino ^a   Riond, Barbara ^a   Willi, Barbara ^a   Meli, Marina L ^a   Rentsch, Katharina M ^b   Hosie, Margaret J ^c   Hofmann Lehmann, Regina ^a   Lutz, Hans ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

Author keywords

Antiretroviral therapy; Feline leukemia virus; Immune response, raltegravir; Retrovirus; Viral loads

Indexed keywords

RALTEGRAVIR; VIRUS ANTIBODY; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANEMIA; ANIMAL MODEL; ANTIVIRAL THERAPY; ARTICLE; CAT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FELINE LEUKEMIA; FELINE LEUKEMIA VIRUS; IN VIVO STUDY; INFECTION SENSITIVITY; MALE; NONHUMAN; OUTCOME ASSESSMENT; REBOUND; SHORT COURSE THERAPY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; DRUG EFFECTS; GENETICS; GERMFREE ANIMAL; LEUKEMIA, FELINE; LYMPHOMA; VIREMIA;

FELINE LEUKEMIA VIRUS; GAMMARETROVIRUS;

ANIMALS; ANTI-HIV AGENTS; CATS; LEUKEMIA VIRUS, FELINE; LEUKEMIA, FELINE; LYMPHOMA; RALTEGRAVIR POTASSIUM; RNA, VIRAL; SPECIFIC PATHOGEN-FREE ORGANISMS; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 84922640292     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2014.10.031     Document Type: Article

References (60)

1. Akhtardanesh B., Ziaali N., Sharifi H., Rezaei S. Feline immunodeficiency virus, feline leukemia virus and Toxoplasma gondii in stray and household cats in Kerman-Iran: seroprevalence and correlation with clinical and laboratory findings. Res. Vet. Sci. 2010, 89:306-310.
2. Bar-Magen T., Sloan R.D., Donahue D.A., Kuhl B.D., Zabeida A., Xu H., Oliveira M., Hazuda D.J., Wainberg M.A. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 2010, 84:9210-9216.
3. Blanco K., Prendas J., Cortes R., Jimenez C., Dolz G. Seroprevalence of viral infections in domestic cats in Costa Rica. J. Vet. Med. Sci. 2009, 71:661-663.
4. Boenzli E., Robert-Tissot C., Sabatino G., Cattori V., Meli M.L., Gutte B., Rovero P., Flynn N., Hofmann-Lehmann R., Lutz H. In vitro inhibition of feline leukaemia virus infection by synthetic peptides derived from the transmembrane domain. Antivir. Ther. 2011, 16:905-913.
5. Boyd M. Dolutegravir-a promising antiretroviral in development. Lancet Infect. Dis. 2012, 12:90-91.
6. Cattori V., Pepin A.C., Tandon R., Riond B., Meli M.L., Willi B., Lutz H., Hofmann-Lehmann R. Real-time PCR investigation of feline leukemia virus proviral and viral RNA loads in leukocyte subsets. Vet. Immunol. Immunopathol. 2008, 123:124-128.
7. Cattori V., Weibel B., Lutz H. Inhibition of Feline leukemia virus replication by the integrase inhibitor Raltegravir. Vet. Microbiol. 2011, 152:165-168.
8. Court M.H., Greenblatt D.J. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics 2000, 10:355-369.
9. Cunningham M.W., Brown M.A., Shindle D.B., Terrell S.P., Hayes K.A., Ferree B.C., McBride R.T., Blankenship E.L., Jansen D., Citino S.B., Roelke M.E., Kiltie R.A., Troyer J.L., O'Brien S.J. Epizootiology and management of feline leukemia virus in the Florida puma. J. Wildl. Dis. 2008, 44:537-552.
10. de Mari K., Maynard L., Sanquer A., Lebreux B., Eun H.M. Therapeutic effects of recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline immunodeficiency virus (FIV)-coinfected symptomatic cats. J. Vet. Intern. Med. 2004, 18:477-482.
11. Domenech A., Miro G., Collado V.M., Ballesteros N., Sanjose L., Escolar E., Martin S., Gomez-Lucia E. Use of recombinant interferon omega in feline retrovirosis: from theory to practice. Vet. Immunol. Immunopathol. 2011, 143:301-306.
12. Duarte A., Castro I., Pereira da Fonseca I.M., Almeida V., Madeira de Carvalho L.M., Meireles J., Fazendeiro M.I., Tavares L., Vaz Y. Survey of infectious and parasitic diseases in stray cats at the Lisbon Metropolitan Area, Portugal. J. Feline Med. Surg. 2010, 12:441-446.
13. Geret C., Riond B., Cattori V., Meli M., Hofmann-Lehmann R., Lutz H. Housing and care of laboratory cats: from requirements to practice. Schweiz. Arch. Tierheilkd. 2011, 153:157-164.
14. Geret C.P., Cattori V., Meli M.L., Riond B., Martinez F., Lopez G., Vargas A., Simon M.A., Lopez-Bao J.V., Hofmann-Lehmann R., Lutz H. Feline leukemia virus outbreak in the critically endangered Iberian lynx (Lynx pardinus): high throughput sequencing of envelope variable region A and experimental transmission. Arch. Virol. 2011, 156:839-854.
15. Geret C.P., Cattori V., Meli M.L., Riond B., Martinez F., Lopez G., Vargas A., Simon M.A., Lopez-Bao J.V., Hofmann-Lehmann R., Lutz H. Feline leukemia virus outbreak in the critically endangered Iberian lynx (Lynx pardinus): high-throughput sequencing of envelope variable region A and experimental transmission. Arch. Virol. 2011, 156:839-854.
16. Gomes-Keller M.A. Feline Leukemia Virus Infection: New Aspects of Pathogenesis as a Consequence of the Infection Pressure 2011, University of Zurich, Zurich, Dissertation.
17. Greggs W.M., Clouser C.L., Patterson S.E., Mansky L.M. Discovery of drugs that possess activity against feline leukemia virus. J. Gen. Virol. 2012, 93:900-905.
18. Hare S., Smith S.J., Metifiot M., Jaxa-Chamiec A., Pommier Y., Hughes S.H., Cherepanov P. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol. Pharmacol. 2011, 80:565-572.
19. Hartmann K., Donath A., Beer B., Egberink H.F., Horzinek M.C., Lutz H., Hoffmann-Fezer G., Thum I., Thefeld S. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet. Immunol. Immunopathol. 1992, 35:167-175.
20. Helfer-Hungerbuehler A.K., Cattori V., Boretti F.S., Ossent P., Grest P., Reinacher M., Henrich M., Bauer E., Bauer-Pham K., Niederer E., Holznagel E., Lutz H., Hofmann-Lehmann R. Dominance of highly divergent feline leukemia virus A progeny variants in a cat with recurrent viremia and fatal lymphoma. Retrovirology 2010, 7:14.
21. Hocqueloux L., Prazuck T., Avettand-Fenoel V., Lafeuillade A., Cardon B., Viard J.P., Rouzioux C. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010, 24:1598-1601.
22. Hofmann-Lehmann R., Cattori V., Tandon R., Boretti F.S., Meli M.L., Riond B., Lutz H. How molecular methods change our views of FeLV infection and vaccination. Vet. Immunol. Immunopathol. 2008, 123:119-123.
23. Hofmann-Lehmann R., Cattori V., Tandon R., Boretti F.S., Meli M.L., Riond B., Pepin A.C., Willi B., Ossent P., Lutz H. Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up. Vaccine 2007, 25:5531-5539.
24. Hofmann-Lehmann R., Holznagel E., Aubert A., Ossent P., Reinacher M., Lutz H. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection. Vet. Immunol. Immunopathol. 1995, 46:127-137.
25. Hofmann-Lehmann R., Huder J.B., Gruber S., Boretti F., Sigrist B., Lutz H. Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats. J. Gen. Virol. 2001, 82:1589-1596.
26. Hofmann-Lehmann R., Tandon R., Boretti F.S., Meli M.L., Willi B., Cattori V., Gomes-Keller M.A., Ossent P., Golder M.C., Flynn J.N., Lutz H. Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays. Vaccine 2006, 24:1087-1094.
27. Jarrett O., Laird H.M., Hay D. Determinants of the host range of feline leukaemia viruses. J. Gen. Virol. 1973, 20:169-175.
28. Kassahun K., McIntosh I., Cui D., Hreniuk D., Merschman S., Lasseter K., Azrolan N., Iwamoto M., Wagner J.A., Wenning L.A. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 2007, 35:1657-1663.
29. Katlama C., Murphy R. Dolutegravir for the treatment of HIV. Expert Opin. Invest. Drugs 2012, 21:523-530.
30. Koelsch K.K., Boesecke C., McBride K., Gelgor L., Fahey P., Natarajan V., Baker D., Bloch M., Murray J.M., Zaunders J., Emery S., Cooper D.A., Kelleher A.D. Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 2011, 25:2069-2078.
31. Koh Y., Matreyek K.A., Engelman A. Differential sensitivities of retroviruses to integrase strand transfer inhibitors. J. Virol. 2011, 85:3677-3682.
32. Lehmann R., Franchini M., Aubert A., Wolfensberger C., Cronier J., Lutz H. Vaccination of cats experimentally infected with feline immunodeficiency virus, using a recombinant feline leukemia virus vaccine. J. Am. Vet. Med. Assoc. 1991, 199:1446-1452.
33. Lewis M.G., DaFonseca S., Chomont N., Palamara A.T., Tardugno M., Mai A., Collins M., Wagner W.L., Yalley-Ogunro J., Greenhouse J., Chirullo B., Norelli S., Garaci E., Savarino A. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS 2011, 25:1347-1356.
34. Lewis M.G., Norelli S., Collins M., Barreca M.L., Iraci N., Chirullo B., Yalley-Ogunro J., Greenhouse J., Titti F., Garaci E., Savarino A. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 2010, 7:21.
35. Lutz H., Addie D., Belak S., Boucraut-Baralon C., Egberink H., Frymus T., Gruffydd-Jones T., Hartmann K., Hosie M.J., Lloret A., Marsilio F., Pennisi M.G., Radford A.D., Thiry E., Truyen U., Horzinek M.C. Feline leukaemia. ABCD guidelines on prevention and management. J. Feline Med. Surg. 2009, 11:565-574.
36. Lutz H., Pedersen N., Higgins J., Harris H., Theilen G. Quantitation of p27 in the serum of cats during natural infection with feline leukemia virus. Development in Cancer Res. 1980, 497-505. Elsevier, North Holland. W.D. Hardy, M. Essex, A. McClelland (Eds.).
37. Lutz H., Pedersen N., Higgins J., Hubscher U., Troy F.A., Theilen G.H. Humoral immune reactivity to feline leukemia virus and associated antigens in cats naturally infected with feline leukemia virus. Cancer Res. 1980, 40:3642-3651.
38. Lutz H., Pedersen N.C., Theilen G.H. Course of feline leukemia virus infection and its detection by enzyme-linked immunosorbent assay and monoclonal antibodies. Am. J. Vet. Res. 1983, 44:2054-2059.
39. Mathes L.E., Pandey R., Chakrabarti R., Hofman F.M., Hayes K.A., Stromberg P., Roy-Burman P. Pathogenicity of a subgroup C feline leukemia virus (FeLV) is augmented when administered in association with certain FeLV recombinants. Virology 1994, 198:185-195.
40. Meli M.L., Cattori V., Martinez F., Lopez G., Vargas A., Simon M.A., Zorrilla I., Munoz A., Palomares F., Lopez-Bao J.V., Pastor J., Tandon R., Willi B., Hofmann-Lehmann R., Lutz H. Feline leukemia virus and other pathogens as important threats to the survival of the critically endangered Iberian lynx (Lynx pardinus). PLoS One 2009, 4:e4744.
41. Merck ISENTRESS™ (raltegravir) 400mg for treatment of HIV (NDA 22-145). FDA Antiviral Drugs Advisory Committee Meeting 2007.
42. Min S., Song I., Borland J., Chen S., Lou Y., Fujiwara T., Piscitelli S.C. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 2010, 54:254-258.
43. Museux K., Boretti F.S., Willi B., Riond B., Hoelzle K., Hoelzle L.E., Wittenbrink M.M., Tasker S., Wengi N., Reusch C.E., Lutz H., Hofmann-Lehmann R. In vivo transmission studies of 'Candidatus Mycoplasma turicensis' in the domestic cat. Vet. Res. 2009, 40:45.
44. Paprotka T., Venkatachari N.J., Chaipan C., Burdick R., Delviks-Frankenberry K.A., Hu W.S., Pathak V.K. Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs. J. Virol. 2010, 84:5719-5729.
45. Prada N., Markowitz M. Novel integrase inhibitors for HIV. Expert Opin. Invest. Drugs 2010, 19:1087-1098.
46. Rentsch K.M. Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 2003, 788:339-350.
47. Robert-Tissot C., Ruegger V.L., Cattori V., Meli M.L., Riond B., Gomes-Keller M.A., Vogtlin A., Wittig B., Juhls C., Hofmann-Lehmann R., Lutz H. The innate antiviral immune system of the cat: molecular tools for the measurement of its state of activation. Vet. Immunol. Immunopathol. 2011, 143:269-281.
48. Robert-Tissot C., Ruegger V.L., Cattori V., Meli M.L., Riond B., Moore P.F., Engels M., Franchini M., Hofmann-Lehmann R., Lutz H. Stimulation with a class A CpG oligonucleotide enhances resistance to infection with feline viruses from five different families. Vet. Res. 2011, 43:60.
49. Sheets R.L., Pandey R., Jen W.C., Roy-Burman P. Recombinant feline leukemia virus genes detected in naturally occurring feline lymphosarcomas. J. Virol. 1993, 67:3118-3125.
50. Shrestha B., Reed J.M., Starks P.T., Kaufman G.E., Goldstone J.V., Roelke M.E., O'Brien S.J., Koepfli K.P., Frank L.G., Court M.H. Evolution of a major drug metabolizing enzyme defect in the domestic cat and other felidae: phylogenetic timing and the role of hypercarnivory. PLoS One 2011, 6:e18046.
51. Singh I.R., Gorzynski J.E., Drobysheva D., Bassit L., Schinazi R.F. Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One 2010, 5:e9948.
52. Smith R.A., Gottlieb G.S., Miller A.D. Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. Retrovirology 2010, 7:70.
53. Song I., Min S.S., Borland J., Lou Y., Chen S., Ishibashi T., Wajima T., Piscitelli S.C. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J. Acquir. Immune Defic. Syndr. 2010, 55:365-367.
54. Stuetzer B., Brunner K., Lutz H., Hartmann K. A trial with 3'-azido-2',3'-dideoxythymidin and human interferon-alpha in cats naturally infected with feline leukaemia virus. J. Feline Med. Surg. 2013, 15:667-671.
55. Tandon R., Cattori V., Gomes-Keller M.A., Meli M.L., Golder M.C., Lutz H., Hofmann-Lehmann R. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. J. Virol. Methods 2005, 130:124-132.
56. Tandon R., Cattori V., Pepin A.C., Riond B., Meli M.L., McDonald M., Doherr M.G., Lutz H., Hofmann-Lehmann R. Association between endogenous feline leukemia virus loads and exogenous feline leukemia virus infection in domestic cats. Virus Res. 2008, 135:136-143.
57. Tandon R., Cattori V., Willi B., Lutz H., Hofmann-Lehmann R. Quantification of endogenous and exogenous feline leukemia virus sequences by real-time PCR assays. Vet. Immunol. Immunopathol. 2008, 123:129-133.
58. Tandon R., Cattori V., Willi B., Meli M.L., Gomes-Keller M.A., Lutz H., Hofmann-Lehmann R. Copy number polymorphism of endogenous feline leukemia virus-like sequences. Mol. Cell. Probes 2007, 21:257-266.
59. Weissenbacher S., Riond B., Hofmann-Lehmann R., Lutz H. Evaluation of a novel haematology analyser for use with feline blood. Vet. J. 2011, 187:381-387.
60. Wills T., Vega V. Elvitegravir: a once-daily inhibitor of HIV-1 integrase. Expert Opin. Invest. Drugs 2012, 21:395-401.